ReviewCritical care (London, England)2025
Targeting high circulating dipeptidyl peptidase 3 in circulatory failure.
Review in Critical care (London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Trial
- Circulating dipeptidyl peptidase 3 and outcomes in acute heart failure: an analysis of the STRONG-HF and CORTAHF studies.ESC heart failure · 2026Trial
- Article
- Influence of adrenomedullin on the enzymatic activity of dipeptidyl peptidase 3Journal of enzyme inhibition and medicinal chemistry · 2026Article
- Use of Natriuretic Peptides in Critically Ill Patients: A Narrative Review.Journal of clinical medicine · 2026Review
- Toward endotype-guided renin-angiotensin-aldosterone system modulation in septic shock.Critical care (London, England) · 2026Article
- Prognosis of critically ill patients with severe acute kidney injury and high circulating dipeptidyl peptidase 3: a post hoc analysis of the AKIKI 2 trial.Critical care (London, England) · 2026Article
- Novel aspects of the renin-angiotensin-aldosterone system in septic shock.Current opinion in physiology · 2026Article
- One Enzyme, Many Faces: The Expanding Role of DPP3 in Cardiovascular and Critical Care.Journal of clinical medicine · 2025Review
- Circulating biomarkers of vasoplegia: a systematic review.Annals of intensive care · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Circulating dipeptidyl peptidase 3 is a new biomarker linked to circulatory failure prognosis and pathophysiology and is a potential actionable therapeutic target. In this short review intended for the clinician, a question-and-answer format provides key insights on the nature of this biomarker and the therapeutical potential of its targeted inhibition in critically ill patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.